Quotient Sciences, a global drug development and manufacturing organization has been recognized as a “Top CMO in Europe for 2021 by PharmaTech Outlook magazine.
This recognition was awarded to only 10 companies that are considered to be at the forefront of providing contract manufacturing organization (CMO) solutions and tranforming businesses.
Quotient has been recognized with multiple 2021 CRO Leadership Awards, including two Champion Awards. The CRO Leadership Awards recognizes top performing outsourcing organizations in the drug development arena.
Quotient received leadership awards in five of the overall six categories.
Quotient Sciences, a global drug development and manufacturing organization has been recognized as a “Top Pharma and Life Sciences Outsourcing Services Company in the UK for 2020” by PharmaTech Outlook magazine.
This recognition was awarded to only 5 companies that are considered to be at the forefront of providing pharmaceutical and life science outsourcing solutions and transforming businesses.
Quotient Sciences (“Quotient”), the innovative drug development and manufacturing organization, has won the Deal of the Year award at the 2019 Medilink East Midlands Business Awards, held on 5th December.
The Deal of the Year award, sponsored by BioCity, recognises entrepreneurship of an individual or team in executing a truly transformational and high-value deal for both the company and the East Midlands Life Sciences sector.
Quotient Sciences (“Quotient”), the drug development services organization, has won the Outstanding Achievement Award at the 2019 Medilink UK Healthcare Business Awards, held last night.
The Awards recognize organizations who have made significant contributions to life sciences and who have excelled in their individual categories across the healthcare industry. The Medilink UK winners were chosen from an exclusive shortlist comprised entirely of winners from each of the regional Medilink awards.
Quotient Sciences, the drug development services organization, announced that it has received a Transatlantic Growth Award at a ceremony hosted by BritishAmerican Business in London on Wednesday, 8th May. The award, in the UK SME in the US category, was presented to Gordon Cameron, CFO, Quotient Sciences.
The award recognises UK companies that have made significant investments across the Atlantic in the last year. Quotient’s US investment included the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, PA. The $15 million investment is helping to build a Centre of Excellence for early-phase formulation development and clinical trial manufacturing.
Quotient Sciences, the unique and innovative provider of drug development services, today announced it has received a British Private Equity & Venture Capital Association (BVCA) Management Team Award.
Quotient’s Mark Egerton receiving BVCA Award
Recognised as the outstanding business in the Large Company category, the national award was presented to Quotient’s CEO Mark Egerton, and CFO Gordon Cameron, at last night’s annual BVCA Gala Dinner at the London Hilton on Park Lane.
Quotient Sciences is delighted to receive a BVCA Management Team Award in the category of “Large Company”. The Award was presented to CEO Mark Egerton and CFO Gordon Cameron at last night’s annual BVCA Midlands Dinner in Birmingham.
Now in its eighth year, the BVCA Management Team Awards recognise and reward the achievements and success of businesses across the UK which are backed by private equity and venture capital funds.